This information is intended for global use. Please consult the appropriate country-specific Baxter website for more information. Some statements about products or procedures may differ from the licensed indications in specific countries. Therefore, always consult the country-specific summary of product characteristics (SPC), package leaflets or instructions for use. For more information, please contact a local Baxter representative.
The technologies in which we have special expertise - polysaccharide carrier protein conjugation, recombinant expression systems and cell culture - have the potential to open the door to a whole new generation of vaccines, to protect against both bacteria and viruses.
At our research center, in Orth an der Donau, Austria, our scientists are working to apply these technologies both to new vaccines and also to improve the performance of Baxter's already marketed vaccines. Currently we have two products on the market: a vaccine against tick-borne encephalitis (TBE) and a vaccine against group C meningococcal meningitis.
Baxter has developed a unique technology platform to manufacture Influenza vaccines at an industrial scale based on its proprietary serum protein free Vero cell technology, which can be used for the production of both seasonal and pandemic vaccines.
In March 2009, Baxter was the first to receive a cell culture-based H5N1pandemic mock up license from the European Medicines Agency (EMEA).
In October 2009, Baxter received the marketing authorization for the first cell culture-based, non-adjuvanted H1N1 pandemic influenza vaccine in the European Union.
Baxter continues to deliver vaccine to national public health authorities that have agreements with the company. Vaccines have already been received by a number of countries, including the UK, Ireland, New Zealand, Germany and Austria, for use in their national vaccination programs.